Phase 2 Study of YA-101 Compared to Placebo Evaluating Safety and Effectiveness in Adults With Multiple System Atrophy

What this Trial Is About

Researchers are evaluating the safety, tolerability, pharmacokinetics, and potential effectiveness of YA-101 in people with multiple system atrophy MSA, a rare neurological condition. This Phase 2, double-blind, placebo-controlled, multi-center study aims to compare two doses of YA-101 against a placebo. The study is designed to gather important information on how the drug behaves in the body and its impact on symptoms of MSA. Participants will be randomly assigned to receive either YA-101 or a placebo, both taken twice daily. The study includes a dose escalation approach to assess the effects of different doses. The treatment period lasts up to 112 days, during which safety and response to the drug will be closely monitored. During the trial, participants will have regular assessments including evaluations of adverse events, drug concentration in the blood, and changes in MSA symptoms using scales such as the Unified Multiple System Atrophy Rating Scale and a 10-meter walking test. Safety tests will also be conducted to track any side effects. The total study participation spans from baseline through Day 112, with careful monitoring to understand the drugs effects and tolerability.

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy